scholarly journals Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid

2015 ◽  
Vol 18 (7) ◽  
pp. pyv021-pyv021 ◽  
Author(s):  
H. Li ◽  
X. Wang ◽  
Y. Zhou ◽  
G. Ni ◽  
Q. Su ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Weight Gain ◽  
Gene Polymorphisms ◽  
Ankk1 Gene

scholarly journals Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy

Seizure ◽  
2015 ◽  
Vol 33 ◽  
pp. 76-80 ◽  
Author(s):  
Kazuyuki Inoue ◽  
Toshiki Takahashi ◽  
Yoshiaki Yamamoto ◽  
Eri Suzuki ◽  
Yukitoshi Takahashi ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Glutamine Synthetase ◽  
Gene Polymorphisms ◽  
Glutamine Synthetase Gene

scholarly journals Valproic Acid Inhibits Leptin Secretion and Reduces Leptin Messenger Ribonucleic Acid Levels in Adipocytes

Endocrinology ◽  
2004 ◽  
Vol 145 (12) ◽  
pp. 5493-5503 ◽  
Author(s):  
Diane C. Lagace ◽  
Roger S. McLeod ◽  
Mark W. Nachtigal
Keyword(s):  
Valproic Acid ◽  
Fatty Acid ◽  
Weight Gain ◽  
Fatty Acid Metabolism ◽  
Acid Metabolism ◽  
Binding Protein ◽  
Mrna Levels ◽  
Dependent Manner ◽  
Messenger Ribonucleic Acid ◽  
Triacylglycerol Synthesis

Abstract Treatment of epilepsy or bipolar disorder with valproic acid (VPA) induces weight gain and increased serum levels for the satiety hormone, leptin, through an unidentified mechanism. In this study we tested the effects of VPA, a short-chain branched fatty acid (C8:0), on leptin biology and fatty acid metabolism in 3T3-L1 adipocytes. VPA significantly reduced leptin secretion in a dose-dependent manner. Because fatty acid accumulation has been hypothesized to block leptin secretion, we tested the effect of VPA on fatty acid metabolism. Using 14C-radiolabeled VPA, we found that the 14C was mainly incorporated into triacylglycerol. VPA did not alter lipogenesis from acetate, nor did it change the amount of intracellular free fatty acids available for triacylglycerol synthesis. Decreased leptin secretion was accompanied by a reduction in leptin mRNA, even though VPA treatment did not alter the protein levels for known transcription factors affecting leptin transcription including: CCAAT/enhancer binding protein-α, peroxisome proliferator-activated receptor-γ, or steroid regulatory element binding protein 1a. VPA altered levels of leptin mRNA independent of de novo protein synthesis without affecting leptin mRNA degradation. This report demonstrates that VPA decreases leptin secretion and mRNA levels in adipocytes in vitro, suggesting that VPA therapy may be associated with altered leptin homeostasis contributing to weight gain in vivo.

Poster #110 NO ASSOCIATION BETWEEN SNAP-25 GENE POLYMORPHISMS AND WEIGHT GAIN IN ANTIPSYCHOTIC TREATMENT OF SCHIZOPHRENIA

2012 ◽  
Vol 136 ◽  
pp. S225
Author(s):  
Aziz Ferchiou ◽  
Anne Dumaine Mohamed Lajnef ◽  
Christophe Laçon ◽  
Pierre Michel Llorca ◽  
Stephane Jamain ◽  
...  
Keyword(s):  
Weight Gain ◽  
Gene Polymorphisms ◽  
Antipsychotic Treatment

scholarly journals Influence of sodium valproate treatment on body mass and insulin resistance parameters in children with epilepsy

2020 ◽  
pp. 84-84
Author(s):  
Aleksandar Dimitrijevic ◽  
Radan Stojanovic ◽  
Dragana Bogicevic ◽  
Vesna Mitic ◽  
Dimitrije Nikolic
Keyword(s):  
Valproic Acid ◽  
Weight Gain ◽  
Sodium Valproate ◽  
Glucose Homeostasis ◽  
Acid Treatment ◽  
Statistical Significance ◽  
Insulin Level ◽  
Serum Glucose ◽  
Drug Discontinuation ◽  
Healthy Children

Introduction/Objective. One of the main side-effects in patients undergoing valproic acid treatment is weight gain. Weight gain might be the reason for drug discontinuation, especially in adolescent girls, and it has to be considered also before introducing the drug. The main goal of our study is to investigate a possible influence of antiepileptic therapy with sodium valproate on weight and glucose homeostasis in pediatric patients with epilepsy. Methods. The investigation included a total of 49 healthy children with recently diagnosed epilepsy. We measured height, weight and serum 12-hour overnight fasting glucose and insulin level before initiation and after 6- and 12-month valproic acid treatment period. The BMI and HOMA indexes were calculated for each patient and correlated after the initiation of therapy and after 6 and 12 months of therapy. Results. We found that children significantly gained weight with statistical significance (p<0.01) even after 6 months of therapy with a significant glucose metabolism change and statistical difference in average serum glucose and insulin levels (p<0.05). Conclusion. Our results show that a 12-month treatment with valproic acid in children with epilepsy has a great impact on weight gain and glucose homeostasis and metabolism. We strongly recommend that all children with recently diagnosed epilepsy at the initiation of valproate therapy should be closely monitored on a 6-month basis. Consultation of nutritionist is advised especially in children with preexisting problem with body weight.

CYP2C19 & UGT1A6 genetic polymorphisms and its impact on Valproic acid-induced weight gain in people with epilepsy: Prospective genetic association study

2021 ◽  
pp. 106786
Author(s):  
Balachandran Mani ◽  
Pradeep Pankajakshan Nair ◽  
Anamika Sekhar ◽  
Sadishkumar kamalanathan ◽  
Sunil K. Narayan ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Weight Gain ◽  
Association Study ◽  
Genetic Polymorphisms ◽  
Genetic Association ◽  
Genetic Association Study

SNAP-25 gene polymorphisms and weight gain in schizophrenic patients

2008 ◽  
Vol 42 (12) ◽  
pp. 963-970 ◽  
Author(s):  
Richard Musil ◽  
Ilja Spellmann ◽  
Michael Riedel ◽  
Sandra Dehning ◽  
Anette Douhet ◽  
...  
Keyword(s):  
Weight Gain ◽  
Gene Polymorphisms ◽  
Schizophrenic Patients

scholarly journals Weight Gain in Epileptic Patients During Treatment with Valproic Acid: a Retrospective Study

1997 ◽  
Vol 24 (3) ◽  
pp. 240-244 ◽  
Keyword(s):  
Body Mass Index ◽  
Valproic Acid ◽  
Body Weight ◽  
Weight Gain ◽  
Body Mass ◽  
Common Adverse Effect ◽  
Drug Dose ◽  
Patient Interviews ◽  
Weight Problems ◽  
History Of

ABSTRACT:Background:Weight gain has been recognized as a common adverse effect of valproic acid (VPA) that leads to discontinuation in some patients but its incidence and correlates have been rarely studied.Methods:We have analyzed the records retrospectively and interviewed 70 adult patients attending an epilepsy clinic on VPA mono- or polytherapy followed over a median of 27 months (range 3-189), as well as 20 patients on carbamazepine (CBZ) monotherapy. Patients were divided into non-weight gainers (< 5% baseline body weight), mild-moderate weight gainers (5-10% body weight) and marked weight gainers (> 10% body weight). The following variables were statistically analyzed to determine their relationship to weight gain: gender, age, body mass index, drug dose, personal or family history of obesity and monotherapy versus polytherapy.Results:Seventy-one percent of the VPA group were weight gainers versus 43% in the CBZ group. A weight gain of more than 4 kg in 70% of the VPA group was observed. The weight gain was often sustained and frequently socially significant to the patients. Patients below or within normal range body mass index prior to the start of VPA experienced the most severe percentage weight gain. From the structured patient interviews, patients with no personal history of weight problems experienced the greatest initial weight increase.Conclusion:Strategies should be devised to help patients avoid weight gain when starting on VPA, especially if they are not already overweight.

Sign in / Sign up

Export Citation Format

Share Document